The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

What Was Tested

This registered early phase 1 trial tested Glutathione.

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups.

Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium.

Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status.

It had two arms (groups): No Multivitamin and Magnesium (experimental) and Multivitamin and Magnesium (active comparator).

The registry classes the interventions as drug.

Who Took Part

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Glutathione and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Glutathione, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2025-06 with completion listed for 2025-09.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC) (time frame: Symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy). Change in Quality of Life Using SF-36 Survey (time frame: Will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy). COVID Severity of Symptoms Questionnaire (time frame: Day 15, 28, end of months 2, 3, 4).

What This Means in Plain Language

Put simply, this is a early phase 1, randomized trial of Glutathione in people.

It was withdrawn before enrolling anyone; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Glutathione compound page, all human trials.